Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis
- 7 August 2009
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 69 (16), 1774-1780
- https://doi.org/10.1002/pros.21027
Abstract
INTRODUCTION AND OBJECTIVES Prostatic inflammation could be a key component in prostate enlargement and benign prostatic hyperplasia (BPH) progression. Our aim was to characterize inflammatory cells infiltrate within BPH tissue and to correlate inflammation and clinical data. MATERIAL AND METHODS Inflammation was profiled on three clinical outcome tissue microarrays (TMAs), including 282 patients treated by surgery for a complicated and/or symptomatic BPH. Inflammation score was defined by combining six cytological parameters and five markers on immunohistochemistry (IHC). Cytological parameters were lymphocytes, macrophages, and polynuclears leukocytes infiltrates, and three glandular aspect modifications: glandular atrophy, glandular destruction, and tissue fibrosis. IHC markers were CD3, CD4, and CD8 decorating T‐lymphocytes, CD20 decorating B‐lymphocytes, and CD163 decorating macrophages. RESULTS The majority of patients had inflammatory cells infiltrating BPH tissues: 81% had T‐lymphocytes markers (CD3), 52% had B‐lymphocytes markers (CD20), and 82% had macrophages markers (CD163). IPSS score (21 vs. 12; P = 0.02) and prostate volume (77 cm3 vs. 62 cm3; P = 0.002) were significantly higher in patients with high‐grade prostatic inflammation. CONCLUSION We characterized inflammatory cells infiltrate in a large cohort of surgically treated BPH specimens. The role of inflammation in BPH development was highlighted by the strong correlation between histological inflammation, IPSS, and prostate volume. Prostate enlargement due to chronic inflammatory process may progressively conduce to BPH progression. Therefore, inflammation is a therapeutic target for BPH. Prostate 69: 1774–1780, 2009.Keywords
Funding Information
- Pierre Fabre Médicament
This publication has 19 references indexed in Scilit:
- Inflammation and Benign Prostatic HyperplasiaUrologic Clinics of North America, 2007
- The Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE TrialEuropean Urology, 2007
- The prostate‐associated lymphoid tissue (PALT) is linked to the expression of homing chemokines CXCL13 and CCL21The Prostate, 2007
- Inflammation and Atrophy Precede Prostatic Neoplasia in a PhIP-Induced Rat ModelNeoplasia, 2006
- The macrophage scavenger receptor CD163Immunobiology, 2005
- Combination Therapy with Rofecoxib and Finasteride in the Treatment of Men with Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Hyperplasia (BPH)European Urology, 2005
- Increased expression of lymphocyte‐derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferationThe Prostate, 2002
- Effects of the lipido sterolic extract of serenoa repens (Permixon®) on infiltrating cells and inflammatory markers in prostatic tissues from BPH patientsEuropean Urology Supplements, 2002
- High prevalence of benign prostatic hypertrophy in the communityThe Lancet, 1991
- The prostate: An increasing medical problemThe Prostate, 1990